“The Applicant evaluated the safety of zidesamtinib administered orally twice daily in GLP-compliant 28-day and 13-week repeat-dose general toxicology studies in Wistar-Han rats and Beagle dogs.”
✓ VerifiedFDA multi-discipline review, p. 37Source ↗
Pivotal GLP studies
28-day and 13-week oral twice-daily GLP studies in rats and dogs
“The Applicant evaluated the safety of zidesamtinib administered orally twice daily in GLP-compliant 28-day and 13-week repeat-dose general toxicology studies in Wistar-Han rats and Beagle dogs.”
✓ VerifiedFDA multi-discipline review, p. 37Source ↗
Route in tox
Oral (twice daily)
“The Applicant evaluated the safety of zidesamtinib administered orally twice daily in GLP-compliant 28-day and 13-week repeat-dose general toxicology studies in Wistar-Han rats and Beagle dogs. Oral administration is consistent with the intended clinical route of administration.”
✓ VerifiedFDA multi-discipline review, p. 37Source ↗